A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2004
11/18/2004	US20040229258 Methods of detecting neurological disorders
11/18/2004	US20040229250 Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
11/18/2004	US20040229232 Compositions and methods for the diagnosis and treatment of tumor
11/18/2004	US20040229223 Using receptor binding peptide to treat and prevent pancreatic disorders; peptide mimetics; antidiabetic agents
11/18/2004	US20040229219 Comprises envelope peptide-glycoprotein fusion for use as preventative against respiratory viral infection
11/18/2004	US20040229214 Synthetic peptides immunoreactive with Hepatitis A virus antibodies
11/18/2004	US20040229212 Recombinant human mannan-binding lectin
11/18/2004	US20040229206 Pharmaceutical composition comprising carrier, mannose binding protein heterodimer and a lectin for use in treatment of blood an cell proliferative disorders; myeloablation therapies for treating cancer
11/18/2004	US20040228901 Collagen-based materials and methods for treating synovial joints
11/18/2004	US20040228881 Compositions and methods for modulating neural sprouting
11/18/2004	US20040228872 such as genistein adminstered to sustain release of toxin
11/18/2004	US20040228870 Methods for promoting growth of bone, ligament, and cartilage
11/18/2004	US20040228866 Suppressor genes
11/18/2004	US20040228865 Prevention and treatment of amyloidogenic disease
11/18/2004	US20040228860 Antibodies to a tumor-associated surface antigen for delivery of diagnostic and therapeutic agents
11/18/2004	US20040228857 administration of a human or humanized antibody expressed and glycosylated in a chinese hamster ovaries (CHO) cell expression system to treat T-cell mediated disorders, autoimmune disorders, cancer and infections; vasculitis, arthritis, lupus, psoriasis, multiple sclerosis, graft versus host disease
11/18/2004	US20040228855 Method for treating symptoms of diabetes
11/18/2004	US20040228853 treating degenerative disc disease in an intervertebral disc having a nucleus pulposus by administering a high affinity anti-matrix metalloproteinase (HAAMMP) into an intravertebral disc; does not inhibit non-targeted cells, tissue or proteins; offers aging resistance
11/18/2004	US20040228852 Use of increased molecular-weight hirudin as an anticoagulant in extracorporeal kidney replace therapy
11/18/2004	US20040228851 identifying an agent that reduces the lipid binding activity of an apoE stable folding intermediate, the method comprising by contacting an apoE stable folding intermediate in a solution with a test agent and determining the effect
11/18/2004	US20040228850 comprises an enzyme (liver enzymes and mucopolysacoharidases) and an immunogen; kits; rheumatoid arthritis
11/18/2004	US20040228849 IKB kinase, subunits thereof, and methods of using same
11/18/2004	US20040228846 Methods and reagents for treating glucose metabolic disorders
11/18/2004	US20040228841 Replication-competent herpes simplex virus mediates destruction of neoplastic cells
11/18/2004	US20040228839 Composition and methods for treatment of HIV infection
11/18/2004	US20040228838 Viral interleukin-6
11/18/2004	US20040228836 cancer therapeutic agent comprising a cancer targeting molecule linked to a liver-expressed chemokine (LEC)
11/18/2004	US20040228835 Compositions and methods for modulating vascularization
11/18/2004	US20040228834 Compositions and methods for modulating vascularization
11/18/2004	US20040228833 specific combination of excipients exhibits an increase of bioavailability of the polypeptide; namely a sugar and salting-out salt are present in sustained release composition
11/18/2004	US20040228831 polymeric drug conjugates composed of biologically active agents attached to regular repeating linear co-polymers or branched co-polymers by means of an enzymatically cleavable linker; may be used to modify drug solubility, drug bioavailability, drug residence time, drug absorption characteristics
11/18/2004	US20040228798 A conjugated drug contains virus-like particle is joined to the antigen by a biotin molecule; bioassay; inhibiting HIV infection, viral infection
11/18/2004	DE19882755B4 Ein Fusionsprotein des hEGF und des humanen Angiogenins und ein Verfahren zu dessen Herstellung A fusion protein of hEGF and human angiogenin, and a process for its preparation
11/18/2004	DE10315834A1 Humane Nukleinsäuresequenzen aus Pankreaskarzinomen Nucleic acid sequences from human pancreatic cancer
11/18/2004	DE10297331T5 Behandlung und Diagnose von Insulin-resistenten Zuständen Treatment and diagnosis of insulin-resistant conditions
11/18/2004	DE10261650A1 Verwendung des multifunktionellen Transkriptionsfaktors Yin-Yang-1 und Varianten davon zur Behandlung von Erkrankungen, insbesondere von Typ-1 Diabetes Use of the multifunctional transcription factor Yin Yang 1 and variants thereof for the treatment of diseases, especially of type 1 diabetes
11/18/2004	CA2748661A1 Dermal micro organs, methods and apparatuses for producing and using the same
11/18/2004	CA2525243A1 Use of melanotransferrin (p97) for regulating plasminogen activation and cell migration
11/18/2004	CA2525191A1 Prodrugs cleavable by cd26
11/18/2004	CA2524722A1 Acylated nonadepsipeptides
11/18/2004	CA2524626A1 The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells
11/18/2004	CA2524623A1 Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation
11/18/2004	CA2524610A1 Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
11/18/2004	CA2524571A1 Alzheimer's disease treatment method comprising a beta-amyloid peptide
11/18/2004	CA2524379A1 Methods for treating sinus headache
11/18/2004	CA2524342A1 Glutamate receptor antagonists as neuroprotectives
11/18/2004	CA2524286A1 Nasal administration of the lh-rh analog leuprolide
11/18/2004	CA2524277A1 Arg-pro-pro-gly-phe analogs as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
11/18/2004	CA2524172A1 Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses
11/18/2004	CA2524166A1 Medical devices and methods for inhibiting proliferation of smooth muscle cells
11/18/2004	CA2523932A1 Selective r-cadherin antagonists and methods
11/18/2004	CA2523870A1 Claudins' underexpression as markers of tumor metastasis
11/18/2004	CA2523765A1 Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity
11/18/2004	CA2523414A1 Peptides having an ace inhibiting effect
11/18/2004	CA2523408A1 Peptides for use in treating obesity
11/18/2004	CA2522345A1 Glycopegylation methods and proteins/peptides produced by the methods
11/18/2004	CA2517338A1 Hiv prodrugs cleavable by cd26
11/18/2004	CA2500523A1 Vp2-modified raav vector compositions and uses therefor
11/17/2004	WO2004107200A1 System and method for controlling user interface properties with data
11/17/2004	EP1477564A2 Human synthetases
11/17/2004	EP1477497A1 Humanized immunoglobulins and their production and use
11/17/2004	EP1477496A1 Peg-conjugated pth or peg-conjugated pth derivate
11/17/2004	EP1477185A2 Pneumococcal genes, portions thereof, expression products therefrom and uses of such genes, portions and products
11/17/2004	EP1477183A1 Botulinum toxins for modulating cholinergic controlled secretions
11/17/2004	EP1477182A1 Novel analgesics
11/17/2004	EP1477181A1 Method of stimulating growth and resistance to diseases of aquatic organisms
11/17/2004	EP1477180A1 Inhibitors of proteasomal activity for stimulating bone and hair growth
11/17/2004	EP1477178A2 Health supplements containing phyto-oestrogens, analogues or metabolites thereof
11/17/2004	EP1477176A1 Malleable bone composition for filling bone defects
11/17/2004	EP1476759A2 Diagnostic method for stroke
11/17/2004	EP1476752A1 Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome
11/17/2004	EP1476746A2 Method for discovering pharmacologically active substances
11/17/2004	EP1476574A2 RNA INTERFERENCE MEDIATED INHIBITION OF TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR (IGF-1R) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/17/2004	EP1476564A1 Cooperative oligonucleotides
11/17/2004	EP1476554A1 Novel compound for inhibiting serine proteases and for inhibiting viral infections or viral propagation: rld 8564
11/17/2004	EP1476553A2 Gene for peripheral arterial occlusive disease
11/17/2004	EP1476543A1 Viral variants with altered susceptibility to nucleoside analogs and uses thereof
11/17/2004	EP1476542A1 Agent for inducing or inhibiting an angiogenesis
11/17/2004	EP1476541A2 Novel cytokine zcytor17 ligand
11/17/2004	EP1476540A1 Methods for producing gama delta t cells
11/17/2004	EP1476471A1 Nutraceuticals for the treatment, protection and restoration of connective tissues
11/17/2004	EP1476469A1 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
11/17/2004	EP1476466A1 Management of mucosal viscosity by tff monomer peptides
11/17/2004	EP1476465A1 Method for producing interferon
11/17/2004	EP1476464A1 Variants of the alpha 1 subunit of human ampk
11/17/2004	EP1476461A2 Immune-modulating peptide made of s. aureus enterotoxin b
11/17/2004	EP1476460A2 A nucleic acid encoding a g-protein-coupled receptor; and uses thereof
11/17/2004	EP1476459A2 RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/17/2004	EP1476458A2 Rna interference mediated inhibition of platelet derived growth factor (pdgf) and platelet derived growth factor receptor (pdgfr) gene expression using short interfering nucleic acid (sina)
11/17/2004	EP1476457A2 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SiNA)
11/17/2004	EP1476456A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/17/2004	EP1476421A2 Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative
11/17/2004	EP1476206A1 Compositions comprising undifferentiated fetal cells for the treatment of skin disordes
11/17/2004	EP1476199A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
11/17/2004	EP1476191A2 Oral administration of interferon-tau
11/17/2004	EP1476187A2 Methods of extending corneal graft survival
11/17/2004	EP1476186A1 Use of an inhibitor or antagonist against tissue factor
11/17/2004	EP1476181A2 Polyalkylene polymer compounds and uses thereof
11/17/2004	EP1476180A2 Interleukin-2 mutants with reduced toxicity
11/17/2004	EP1476179A2 Methods of preventing or treating brain ischemia or brain injury

1 ... 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 ... 3163